Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension

Curr Opin Cardiol. 2023 Sep 1;38(5):447-455. doi: 10.1097/HCO.0000000000001069. Epub 2023 Aug 1.

Abstract

Purpose of review: To describe the relationship between three pandemics: hypertension, obesity, and heart failure. From pathophysiology to treatment, understanding how these disease entities are linked can lead to breakthroughs in their prevention and treatment. The relevance of this review lies in its discussion of novel pharmacological and surgical treatment strategies for obesity and hypertension, and their role in the prevention and treatment of heart failure.

Recent findings: Novel medications such as GLP-1 agonists have demonstrated sustained weight loss in patients with obesity, and concurrent improvements in their cardiometabolic profile, and possibly also reductions in hypertension-related comorbidities including heart failure. Surgical therapies including laparoscopic bariatric surgery represent an important treatment strategy in obese patients, and recent studies describe their use even in patients with advanced heart failure, including those with ventricular assist devices.

Summary: These developments have deep implications on our efforts to understand, mitigate, and ultimately prevent the three pandemics, and offer promising improvements to quality of life, survival, and the cost burden of these diseases.

Publication types

  • Review

MeSH terms

  • Bariatric Surgery*
  • Heart Failure* / therapy
  • Humans
  • Hypertension* / complications
  • Hypertension* / therapy
  • Obesity / surgery
  • Obesity / therapy
  • Quality of Life
  • Weight Loss